» Articles » PMID: 27643717

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II

Abstract

This topic addresses the treatment of newly diagnosed patients with favorable prognosis stage I and II Hodgkin lymphoma. In most cases, combined modality therapy (chemotherapy followed by involved site radiation therapy) constitutes the current standard of care. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the appropriate use of combined modality therapy for favorable prognosis stage I and II Hodgkin lymphoma. Increasing information about the late effects of treatment has led to attempts to decrease toxicity by using less chemotherapy (decreased duration and/or intensity or different agents) and less radiation therapy (reduced volume and/or dose) while maintaining excellent efficacy.

Citing Articles

Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma.

Allen P, Winter J Curr Oncol Rep. 2019; 21(5):39.

PMID: 30919161 DOI: 10.1007/s11912-019-0788-0.


Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

Allen P, Gordon L Clin Med Insights Oncol. 2017; 11:1179554917731072.

PMID: 28989291 PMC: 5624347. DOI: 10.1177/1179554917731072.

References
1.
Swerdlow A, Barber J, Hudson G, Cunningham D, Gupta R, Hancock B . Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000; 18(3):498-509. DOI: 10.1200/JCO.2000.18.3.498. View

2.
Diehl V, Sextro M, Franklin J, Hansmann M, Harris N, Jaffe E . Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999; 17(3):776-83. DOI: 10.1200/JCO.1999.17.3.776. View

3.
Swerdlow A, Higgins C, Smith P, Cunningham D, Hancock B, Horwich A . Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007; 99(3):206-14. DOI: 10.1093/jnci/djk029. View

4.
Zinzani P, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E . Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006; 17(8):1296-300. DOI: 10.1093/annonc/mdl122. View

5.
Raemaekers J, Andre M, Federico M, Girinsky T, Oumedaly R, Brusamolino E . Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014; 32(12):1188-94. DOI: 10.1200/JCO.2013.51.9298. View